Trials / Recruiting
RecruitingNCT04925414
Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)
Migraine and High Flow Oxygenotherapy at the Emergency Department
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Migraine is a common pathology, affecting around 12% of the general population, up to 25% in some cohorts, as well as a significant part of the reasons for emergency room visits. Unlike cluster headaches, the use of high-flow oxygen therapy has not yet been validated in patients with migraine. However, several aspects of its pathophysiology, still studied to this day, suggest that the use of normobaric oxygen could have beneficial effects on migraine attacks: tissue hypoxia, cerebrovascular dysfunction with vasodilation, inflammation, etc. In addition, high-flow oxygen therapy has no significant side effects and almost no contraindication (mainly COPD and other chronic respiratory failure) Its use in the event of a migraine attack would thus allow less recourse to conventional analgesics (with significant side effects for some), a shorter stay in the emergency room, and therefore a benefit in terms of cost and relief for the patient. In this context, the sponsor wish to carry out a multicenter prospective interventional, single-blind randomized placebo-controlled in parallel groups study.
Detailed description
Migraine is a common pathology, affecting around 12% of the general population, up to 25% in some cohorts, as well as a significant part of the reasons for emergency room visits. Unlike cluster headaches, the use of high-flow oxygen therapy has not yet been validated in patients with migraine. However, several aspects of its pathophysiology, still studied to this day, suggest that the use of normobaric oxygen could have beneficial effects on migraine attacks: tissue hypoxia, cerebrovascular dysfunction with vasodilation, inflammation, etc. In addition, high-flow oxygen therapy has no significant side effects and almost no contraindication (mainly COPD and other chronic respiratory failure) Its use in the event of a migraine attack would thus allow less recourse to conventional analgesics (with significant side effects for some), a shorter stay in the emergency room, and therefore a benefit in terms of cost and relief for the patient. In this context, the sponsor wish to carry out a multicenter prospective interventional, single-blind randomized placebo-controlled in parallel groups study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oxygenotherapy | High concentration mask delivering 15L/min of oxygen |
| DRUG | placebo air aerosol | High concentration mask delivering 15L/min of air |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2025-04-01
- Completion
- 2025-04-01
- First posted
- 2021-06-14
- Last updated
- 2024-11-18
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04925414. Inclusion in this directory is not an endorsement.